5-Fluorouracil Reduces the Fibrotic Scar Via Inhibiting Matrix Metalloproteinase 9 and Stabilizing Microtubules After Spinal Cord Injury
Overview
Affiliations
Aims: Fibrotic scars composed of a dense extracellular matrix are the major obstacles for axonal regeneration. Previous studies have reported that antitumor drugs promote neurofunctional recovery.
Methods: We investigated the effects of 5-fluorouracil (5-FU), a classical antitumor drug with a high therapeutic index, on fibrotic scar formation, axonal regeneration, and functional recovery after spinal cord injury (SCI).
Results: 5-FU administration after hemisection SCI improved hind limb sensorimotor function of the ipsilateral hind paws. 5-FU application also significantly reduced the fibrotic scar formation labeled with aggrecan and fibronectin-positive components, Iba1 /CD11b macrophages/microglia, vimentin, chondroitin sulfate proteoglycan 4 (NG2/CSPG4), and platelet-derived growth factor receptor beta (PDGFRβ) pericytes. Moreover, 5-FU treatment promoted stromal cells apoptosis and inhibited fibroblast proliferation and migration by abrogating the polarity of these cells and reducing matrix metalloproteinase 9 expression and promoted axonal growth of spinal neurons via the neuron-specific protein doublecortin-like kinase 1 (DCLK1). Therefore, 5-FU administration impedes the formation of fibrotic scars and promotes axonal regeneration to further restore sensorimotor function after SCI.
The Hidden Hand in White Matter: Pericytes and the Puzzle of Demyelination.
Raj S, Sarangi P, Goyal D, Kumar H ACS Pharmacol Transl Sci. 2024; 7(10):2912-2923.
PMID: 39421660 PMC: 11480894. DOI: 10.1021/acsptsci.4c00192.
Lentilhas-Graca J, Santos D, Afonso J, Monteiro A, Pinho A, Mendes V Front Immunol. 2024; 15:1354479.
PMID: 38444856 PMC: 10912310. DOI: 10.3389/fimmu.2024.1354479.
Regenerative medicine strategies for chronic complete spinal cord injury.
Hashimoto S, Nagoshi N, Nakamura M, Okano H Neural Regen Res. 2023; 19(4):818-824.
PMID: 37843217 PMC: 10664101. DOI: 10.4103/1673-5374.382230.
Xu Y, He X, Wang Y, Jian J, Peng X, Zhou L CNS Neurosci Ther. 2022; 28(12):2011-2023.
PMID: 35918897 PMC: 9627390. DOI: 10.1111/cns.13930.